Payment overview · 2025
General Payments
33 reported records · 10 companies
Healthcare provider profile · identity verified
Allopathic & Osteopathic Physicians|Radiology|Vascular & Interventional Radiology · LOS ANGELES, CA · NPI 1558621078
Verified facts
CMS Open Payments records show Adam Nehemiah Plotnik, M.D. received $7,089.41 in general payments during 2025 across 33 reported records.
Merit Medical Systems Inc accounted for 74.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Payment overview · 2025
33 reported records · 10 companies
Separate record types
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Merit Medical Systems Inc | Unresolved — no canonical attribution shown | $5,308.87 | 74.9% | 3 | 2025 |
| Balt USA, LLC | Unresolved — no canonical attribution shown | $741.70 | 10.5% | 7 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$362.12 | 5.1% | 5 | 2025 |
| TriSalus Life Sciences, Inc. | Unresolved — no canonical attribution shown | $196.49 | 2.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $162.54 | 2.3% | 7 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $134.33 | 1.9% | 3 | 2025 |
| Sirtex Medical Inc | Unresolved — no canonical attribution shown | $64.60 | 0.9% | 2 | 2025 |
| Cook Medical LLC | Unresolved — no canonical attribution shown | $59.94 | 0.8% | 3 | 2025 |
| Inari Medical, Inc. | Unresolved — no canonical attribution shown | $29.98 | 0.4% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $28.84 | 0.4% | 1 | 2025 |
What were the payments for?
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $5,267.91 | 2 |
| Food and Beverage | $1,821.50 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Prestige Coil System Normalized: prestige coil system |
Device | Balt USA, LLC | $685.03 | 6 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $284.78 | 2 | 2025 |
Source payment records
|
|||||
| TRINAV INFUSION SYSTEM Normalized: trinav infusion system |
Device | TriSalus Life Sciences, Inc. | $196.49 | 1 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Inari Medical, Inc., Stryker Corporation | $92.67 | 2 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Inari Medical, Inc., Stryker Corporation | $92.67 | 2 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $71.64 | 2 | 2025 |
Source payment records
|
|||||
| SIR-Spheres Microspheres Normalized: sir spheres microspheres |
Device | Sirtex Medical Inc | $64.60 | 2 | 2025 |
Source payment records
|
|||||
| Revere Hybrid Access Catheter Normalized: revere hybrid access catheter |
Device | Balt USA, LLC | $56.67 | 1 | 2025 |
Source payment records
|
|||||
| HAWKONE Normalized: hawkone |
Device | Medtronic, Inc. | $55.01 | 2 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $49.51 | 2 | 2025 |
Source payment records
|
|||||
| DIAMONDBACK PERIPHERAL Normalized: diamondback peripheral |
Device | Abbott Laboratories | $48.10 | 2 | 2025 |
Source payment records
|
|||||
| SUPERA Normalized: supera |
Device | Abbott Laboratories | $45.91 | 2 | 2025 |
Source payment records
|
|||||
| ROSEN Normalized: rosen |
Device | Cook Medical LLC | $45.19 | 2 | 2025 |
Source payment records
|
|||||
| Merit Meastro Microcatheters Normalized: merit meastro microcatheters |
Device | Merit Medical Systems Inc | $40.96 | 1 | 2025 |
Source payment records
|
|||||
| True Form Reshapable Guide Wire Normalized: true form reshapable guide wire |
Device | Merit Medical Systems Inc | $40.96 | 1 | 2025 |
Source payment records
|
|||||
| TheraSphere Y90 Glass Microspheres 10 GBq Normalized: therasphere y90 glass microspheres 10 gbq |
Device | Boston Scientific Corporation | $28.84 | 1 | 2025 |
Source payment records
|
|||||
| CHOCOLATE PTA BALLOON CATHETER Normalized: chocolate pta balloon catheter |
Device | Medtronic, Inc. | $22.33 | 1 | 2025 |
Source payment records
|
|||||
| JETI PERIPHERAL CATHETER Normalized: jeti peripheral catheter |
Device | Abbott Laboratories | $19.02 | 1 | 2025 |
Source payment records
|
|||||
| ZILVER VENA Normalized: zilver vena |
Device | Cook Medical LLC | $14.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 25 |
| Methylprednisolone | Methylprednisolone | 24 | 24 |
| Naproxen | Naproxen | 23 | 23 |
Timeline
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $7,089.41 · 33 records | Merit Medical Systems Inc | CHOCOLATE PTA BALLOON CATHETER, CLOTTRIEVER BOLD CATHETER, CT THROMBECTOMY SYSTEM KIT, DIAMONDBACK PERIPHERAL, ESPRIT, FLOWTRIEVER CATHETER, S, HAWKONE, INTELLIS ADAPTIVESTIM, JETI PERIPHERAL CATHETER, Merit Meastro Microcatheters, Prestige Coil System, ROSEN, Revere Hybrid Access Catheter, SIR-Spheres Microspheres, SUPERA, TRINAV INFUSION SYSTEM, TheraSphere Y90 Glass Microspheres 10 GBq, True Form Reshapable Guide Wire, ZILVER VENA | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error